MedTrace Logo

Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma

NCT03430687 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2020-07-28

No results posted yet for this study

Summary

This phase I trial studies the side effects and best dose of talimogene laherparepvec and to see how well it works in treating patients with non-muscle invasive bladder transitional cell carcinoma. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may attack specific tumor cells and stop them from growing or kill them.

Conditions

  • Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7
  • Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7
  • Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7
  • Stage I Bladder Urothelial Carcinoma AJCC v6 and v7

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Talimogene Laherparepvec

Given intravesically

Sponsors & Collaborators

Principal Investigators

  • Terence Friedlander · University of California, San Francisco

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2019-12-31
Completion
2020-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03430687 on ClinicalTrials.gov